G04CA03 - Terazosin |
Propably not porphyrinogenic |
PNP |
Rationale
No data pointing to CYP-interaction. Two references authorised / use with care.
Chemical description
Used in hypertrophic prostatic disease, 2-5 mg/d. Quinazoline derivative with selective effect on alpha-1-receptors in the bladder, giving rise to relaxation. Metabolized in the liver by hydrolysis and demethylation. No data pointing to CYP-interaction. South African list: use with care. French list: authorized
IPNet drug reports
Uneventful use reported in 3 patients with acute porphyria.
Similar drugs
© NAPOS 2024